Literature DB >> 12151906

Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function.

Bernard Bruguerolle1, Nicolas Simon.   

Abstract

The existence of circadian rhythms and their implication in many pathologic processes have been underlined in several diseases but have not been evaluated in Parkinson's disease. The aim of this paper is to review diurnal variations of clinical, biologic, or experimental factors described with Parkinson's disease. Clinical data often report daily fluctuations of motor activity pattern, but the effect of the stage of the disease and the respective roles of drugs are difficult to evaluate. Sleep disturbances in Parkinson's disease patients also reveal alterations of circadian rhythms. Autonomic dysfunction, described in Parkinson's disease, reveals numerous alterations in circadian regulations including loss of circadian rhythm of blood pressure, increased diurnal blood pressure variability, and postprandial hypotension. Many biologic indices such as cortisol, catecholamines, and melatonin are also altered. Circadian rhythms in dopaminergic systems as well as possible daily fluctuations in kinetics of drug treatments are likely involved in such variations. Few clinical studies have been devoted to circadian patterns of drug response. As for other diseases where biologic rhythms are concerned Parkinson's disease therapy may be influenced by further understanding of circadian influence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151906     DOI: 10.1097/00002826-200207000-00002

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  27 in total

Review 1.  Can music-based movement therapy improve motor dysfunction in patients with Parkinson's disease? Systematic review and meta-analysis.

Authors:  Shuai Zhang; Dong Liu; Dan Ye; Haiyu Li; Feng Chen
Journal:  Neurol Sci       Date:  2017-06-21       Impact factor: 3.307

2.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

3.  Sleep disorders and daytime sleepiness in Parkinson's disease.

Authors:  Renee Monderer; Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

4.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 5.  'The clocks that time us'--circadian rhythms in neurodegenerative disorders.

Authors:  Aleksandar Videnovic; Alpar S Lazar; Roger A Barker; Sebastiaan Overeem
Journal:  Nat Rev Neurol       Date:  2014-11-11       Impact factor: 42.937

6.  CLOCK rs1801260 Polymorphism is Associated with Susceptibility to Parkinson's Disease in a Chinese Population.

Authors:  Fan Lou; Ming Li; Yan Ren; Xiao-Guang Luo; Na Liu; Xiaohong Li
Journal:  Neurosci Bull       Date:  2017-08-05       Impact factor: 5.203

Review 7.  Circadian rhythm connections to oxidative stress: implications for human health.

Authors:  Melissa Wilking; Mary Ndiaye; Hasan Mukhtar; Nihal Ahmad
Journal:  Antioxid Redox Signal       Date:  2013-04-24       Impact factor: 8.401

8.  A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease.

Authors:  Akane Hayashi; Naoya Matsunaga; Hiroyuki Okazaki; Keisuke Kakimoto; Yoshinori Kimura; Hiroki Azuma; Eriko Ikeda; Takeshi Shiba; Mayumi Yamato; Ken-Ichi Yamada; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Neuromolecular Med       Date:  2013-01-05       Impact factor: 3.843

9.  Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine-lesioned rat.

Authors:  K Slack; R Billing; S Matthews; H N Allbutt; R Einstein; J M Henderson
Journal:  Parkinsons Dis       Date:  2010-03-21

Review 10.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.